Thermo Fisher posts Q1 beat, deal

Thermo Fisher Scientific reported first-quarter 2026 results on April 23 that topped analyst expectations, giving the laboratory tools and services company a fresh set of numbers as it expands in diagnostics, manufacturing and oncology-related partnerships. The Waltham, Massachusetts-based company said adjusted earnings per share rose 6% to $5.44 and revenue increased 6% to $11.01 billion for the quarter ended March 28, 2026. (ir.thermofisher.com) Analyst consensus tracked by MarketBeat had called for $5.25 a share on $10.86 billion in revenue. Thermo Fisher said the quarter also included new commercial and research tie-ups, including a U.S. manufacturing agreement announced this week with Nuvation Bio and an earlier research partnership tied to AstraZeneca’s BioVentureHub in Sweden. (ir.thermofisher.com) ### How far ahead of expectations did Thermo Fisher come in? Thermo Fisher said adjusted earnings per share were $5.44 in the first quarter, compared with $5.25 expected by analysts, while revenue reached $11.01 billion against expectations of $10.86 billion. MarketBeat’s earnings page showed the company beat consensus by 19 cents a share and about $144 million in revenue. March 28, 2026 marked the end of the quarter in which Thermo Fisher also posted GAAP diluted earnings per share of $4.43, up 11% from a year earlier. In its earnings release, the company said first-quarter revenue grew 6%, and Chief Executive Marc N. Casper said the results reflected “excellent execution” and progress on strategy. (ir.thermofisher.com) ### What did the company say about demand and business mix? Marc Casper said in the April 23 release that Thermo Fisher delivered a “strong start to the year” and pointed to execution across its portfolio. The company highlighted activity in laboratory instruments, diagnostics-adjacent products and pharmaceutical services, including launches in cryo-electron microscopy, mass spectrometry, handheld X-ray fluorescence and cell therapy manufacturing. (ir.thermofisher.com) Thermo Fisher’s investor relations overview says the company generates annual revenue of more than $45 billion and sells across life sciences research, analytical instruments, specialty diagnostics and pharma services. That scale gives context for why quarterly changes in diagnostics demand and manufacturing contracts are closely watched by investors, although the company did not quantify diagnostics demand separately in the materials reviewed here. (ir.thermofisher.com) ### What is the Nuvation Bio agreement, exactly? Nuvation Bio said on May 13 that it would collaborate with Thermo Fisher Scientific for U.S.-based manufacturing of IBTROZI, its treatment for ROS1-positive non-small cell lung cancer. The announcement appeared in Nuvation Bio’s investor relations news feed two days before this article was written. (ir.thermofisher.com) IBTROZI is the brand name for taletrectinib, according to Nuvation Bio’s recent investor materials and news items. On May 6, the company separately said the U.S. Food and Drug Administration had accepted a supplemental new drug application for IBTROZI with updated duration-of-response data in advanced ROS1-positive non-small cell lung cancer. ### Where does AstraZeneca fit into this story? (ir.thermofisher.com) October 1, 2025 was the date Thermo Fisher’s PPD clinical research business announced a new research and development partnership with AstraZeneca BioVentureHub in Gothenburg, Sweden. Thermo Fisher said a dedicated team would co-locate with AstraZeneca scientists and begin with work in chromatography, molecular genomics and proteomics. (investors.nuvationbio.com) Magnus Björsne, chief executive of AstraZeneca BioVentureHub, said at the time that bringing Thermo Fisher into the campus would create opportunities for “open scientific co-creation.” Thermo Fisher said the partnership sat alongside construction of a future bioanalytical laboratory in Gothenburg that was expected to begin operations in March 2026. (investors.nuvationbio.com) ### What else did Thermo Fisher do during the quarter? Thermo Fisher said the quarter included the completed acquisition of Clario, a provider of endpoint data solutions, $3.0 billion of share repurchases and a 10% dividend increase. The company also announced a strategic collaboration with Nvidia during the quarter and a separate manufacturing-related collaboration with SHL Medical. (ppd.com) May 20, 2026 is Thermo Fisher’s next dated investor event on its calendar, when the company is scheduled to hold its annual meeting of shareholders. The investor relations site also lists first-quarter earnings materials and the latest 10-Q for investors seeking more detail on the quarter ended March 28. (ir.thermofisher.com 1) (ir.thermofisher.com 2) (ppd.com)